Merck (BUE:MRK) Cyclically Adjusted FCF per Share: ARS1,361.02 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:MRK Merck & Co Inc BUE:MRK
69 GF Score
Price ARS41,280.00
GF Value ARS36,549.27
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted FCF per Share?

Merck BUE:MRK -1.85% 69 Cyclically Adjusted FCF per Share is ARS1,361.02 as of Mar. 2026. GuruFocus rates BUE:MRK with a GF Score™ of 69/100 and a GF Value™ of ARS36,549.27 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Merck's adjusted free cash flow per share for the three months ended in Mar. 2026 was ARS16,556.082. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS1,361.02 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Merck's average Cyclically Adjusted FCF Growth Rate was 4.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 5.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Merck was 15.30% per year. The lowest was -3.70% per year. And the median was 5.30% per year.

As of today (2026-07-30), Merck's current stock price is ARS41280.00. Merck's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ARS1,361.02. Merck's Cyclically Adjusted Price-to-FCF of today is 30.33.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 17.07. And the median was 24.04.


Merck  (BUE:MRK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Merck's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=41280.00/1361.02
=30.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Merck was 34.10. The lowest was 17.07. And the median was 24.04.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Merck Cyclically Adjusted FCF per Share Related Terms


Merck Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted FCF per Share Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 136.38 259.56 751.49 1,047.86 1,386.14

Merck Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,171.25 1,089.44 1,426.33 1,386.14 1,361.02

BUE:MRK vs AMGN, ABBV, GILD: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted Price-to-FCF falls into.


BUE:MRK
69GF Score
Merck & Co Inc BUE:MRK
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16556.082/330.2130*330.2130
=16,556.082

Current CPI (Mar. 2026) = 330.2130.

Merck Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 61.403 241.018 84.127
201609 137.174 241.428 187.620
201612 176.006 241.432 240.728
201703 -2.954 243.801 -4.001
201706 175.185 244.955 236.159
201709 -103.586 246.819 -138.585
201712 231.098 246.524 309.550
201803 52.417 249.554 69.359
201806 258.928 251.989 339.306
201809 294.062 252.439 384.660
201812 381.201 251.233 501.039
201903 111.278 254.202 144.552
201906 397.415 256.143 512.337
201909 710.382 256.759 913.609
201912 878.501 256.974 1,128.879
202003 -67.991 258.115 -86.983
202006 755.867 257.797 968.192
202009 212.950 260.280 270.166
202012 824.689 260.474 1,045.490
202103 251.345 264.877 313.343
202106 560.921 271.696 681.730
202109 1,397.683 274.310 1,682.524
202112 1,523.017 278.802 1,803.861
202203 1,598.519 287.504 1,835.981
202206 1,503.178 296.311 1,675.162
202209 2,446.657 296.808 2,722.022
202212 2,158.790 296.797 2,401.845
202303 257.102 301.836 281.273
202306 2,589.051 305.109 2,802.075
202309 9,367.279 307.789 10,049.733
202312 -1,055.580 306.746 -1,136.335
202403 7,381.810 312.332 7,804.418
202406 17,058.148 314.175 17,928.932
202409 31,825.477 315.301 33,330.647
202412 10,012.347 315.605 10,475.776
202503 4,936.370 319.799 5,097.119
202506 11,947.922 322.561 12,231.358
202509 37,157.785 324.800 37,777.043
202512 10,649.702 324.054 10,852.111
202603 16,556.082 330.213 16,556.082

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ARS1,361.02 mean?
Merck (BUE:MRK) has a Cyclically Adjusted FCF per Share of ARS1,361.02 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Merck and its competitors.
Is Merck's Cyclically Adjusted FCF per Share too high?
Merck's current Cyclically Adjusted FCF per Share is ARS1,361.02. Overall, Merck has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Merck's Cyclically Adjusted FCF per Share compare to AMGN and ABBV?
Merck's Cyclically Adjusted FCF per Share of ARS1,361.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Merck and its competitors. Merck's current Cyclically Adjusted FCF per Share is ARS1,361.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (BUE:MRK) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS36,549.27, compared to a current price of ARS41,280.00 — trading 12.9% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ARS1,361.02. Merck's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Merck (BUE:MRK), the current Cyclically Adjusted FCF per Share is ARS1,361.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (BUE:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of ARS41,280.00 is trading 12.9% above its estimated GF Value™ of ARS36,549.27. GuruFocus considers Merck to be Modestly Overvalued.

Key valuation signals for BUE:MRK:

  • Cyclically Adjusted FCF per Share: ARS1,361.02
  • GF Value™: ARS36,549.27 vs. price of ARS41,280.00 (12.9% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the BUE:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
69GF Score

Get the complete analysis for BUE:MRK

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS41,280.00
Price
ARS36,549.27
GF Value